ATI-1777, a Topical Jak1/3 Inhibitor, May Benefit Atopic Dermatitis without Systemic Drug Exposure: Results from Preclinical Development and Phase 2a Randomized Control Study ATI-1777-AD-201.
Changelian P, Xu C, Mnich S, Hope H, Kostecki K, Hirsch J, Loh CY, Anderson D, Blinn J, Hockerman S, Dick E, Smith W, Monahan J, Raoof T, Forman S, Burt D, Barnes B, Gordon D, Walker N, Sudzina J, Tucker S, Jacobsen J.
Changelian P, et al. Among authors: gordon d.
JID Innov. 2023 Nov 28;4(2):100251. doi: 10.1016/j.xjidi.2023.100251. eCollection 2024 Mar.
JID Innov. 2023.
PMID: 38299059
Free PMC article.